Table 3.

Duration of TEAEs of interest among participants taking SXB.

TEAE	SXB-15		SXB-22
	With TEAE, n	Median (Range) Duration, Days	With TEAE, n	Median (Range) Duration, Days
Dizziness	36	9.0 (1.0–69.0)	20	17.5 (1.0–53.0)
Nausea	38	4.5 (1.0–57.0)	29	3.0 (1.0–60.0)
Headache	55	2.0 (1.0–58.0)	—	—

TEAEs that occurred more frequently in participants treated with SXB than placebo and at an incidence ≥5% in any SXB treatment group during week 1 are shown for the all treated population. Data are not shown for headache in SXB-22 because this TEAE did not meet these criteria. SXB = sodium oxybate; TEAE = treatment-emergent adverse event.